Indivior PLC (INDV) Covered Calls

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical leader focused on developing and commercializing evidence-based treatments for opioid use disorder (OUD) and other substance use disorders. The company’s primary revenue driver is SUBLOCADE, a long-acting injectable buprenorphine. Following its 2026 redomiciliation to the United States, Indivior is accelerating its presence in the U.S. market while maintaining a pipeline of non-opioid and long-acting treatments for addiction.

You can sell covered calls on Indivior PLC to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for INDV (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Indivior Pharmaceuticals, Inc. is a global leader in addiction medicine, singularly focused on treating opioid use disorder (OUD) as a chronic brain disease. The company transitioned its corporate domicile from the United Kingdom to the United States in January 2026 to better align with its primary market, which accounts for over 80% of its revenue. Its commercial cornerstone is SUBLOCADE, the first once-monthly injectable buprenorphine formulation designed to provide sustained clinical plasma levels and eliminate the need for daily dosing. The company also maintains a legacy portfolio that includes SUBOXONE sublingual film.

In 2026, Indivior is executing its "Accelerate" agenda, which prioritizes the expansion of long-acting injectable (LAI) penetration in the U.S. Buprenorphine Medication-Assisted Treatment (BMAT) category. This involves an aggressive direct-to-consumer marketing campaign and a focus on specialized channels such as criminal justice systems and organized health systems. By simplifying its global operating model and exiting non-core international markets, the company has redirected its resources toward high-growth opportunities in North America and select European territories.

Competition

The addiction treatment market is highly competitive and sensitive to regulatory shifts and generic entry. Indivior’s primary competition comes from other manufacturers of buprenorphine-based therapies and emerging non-opioid treatments. Key competitors with active options trading on major exchanges include Viatris, Teva Pharmaceutical Industries, and Amgen. The company also faces specialized competition from Ascendis Pharma and firms like Braeburn, which produce rival long-acting injectable products.

Strategic Outlook and Innovation

Strategic innovation at Indivior is centered on diversifying its OUD portfolio and addressing adjacent substance use disorders. The company’s R&D pipeline features INDV-6001, a potential three-month buprenorphine injection designed to offer even greater flexibility and adherence for patients in recovery. Additionally, the company is advancing INDV-2000, a first-in-class, non-opioid candidate for OUD. These efforts are aimed at providing comprehensive care options that address the varying biological and behavioral needs of the patient population while mitigating the risks associated with opioid-based maintenance therapies.

The company is also leveraging its strengthened financial profile to explore strategic business development and M&A opportunities. This includes acquiring next-generation growth drivers that complement its existing addiction science platform. By investing in digital health tools and patient support services, Indivior intends to move beyond traditional pharmacology to offer holistic recovery solutions. The long-term goal is to sustain its market leadership by improving patient outcomes and maintaining a disciplined capital allocation strategy, including significant share repurchase programs enabled by its increased cash flow generation.

Want more examples? INDS Covered Calls | INDY Covered Calls